640 692
[25]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteria in solid tumours: revised RECIST guideline (version 1.1). EJC 2009;45:228–47.[26]
Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760–4.[27]
Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182:517– 25, discussion 525-7.[28]
Ahmad I, Kalna G, Ismail M, et al. Prostate gland lengths and iceball dimensions predict micturition functional outcome following sal- vage prostate cryotherapy in men with radiation recurrent pros- tate cancer. PLoS One 2013;8:e69243.[29]
Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013;86: 324–9.
[30]
Yamada Y, Kollmeier MA, Pei X, et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recur- rent prostate cancer after definitive external beam radiotherapy. Brachytherapy 2014;13:111–6.[31]
Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experi- ence. Int J Radiat Oncol Biol Phys 2007;67:1106–12.
[32]
Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;77:1338–44.[33]
Crouzet S, Murat FJ, Pommier P, et al. Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. Radiother Oncol 2012;105:198–202.[34]
Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of pros- tate cancer: a systematic review of the literature. Eur Urol 2015;67:852–63.
[35]
Karnes RJ, Murphy CR, Bergstralh EJ, et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C- choline positron emission tomography/computerized tomogra- phy. J Urol 2015;193:111–6.[36]
Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatec- tomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomog- raphy. Eur Urol 2011;60:935–43.[37]
Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941–9.[38]
van den Bergh RC, van Casteren NJ, van den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmeta- static disease recurrence after local curative treatment: a system- atic review. Eur Urol 2016;69:802–20.[39]
Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of andro- gen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731–9.
[40]
Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred andro- gen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002:CD003506.[41]
Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reas- sessment of the definition of castrate levels of testosterone: impli- cations for clinical decision making. Urology 2000;56:1021–4.[42]
Morote J, Planas J, Salvador C, Raventos CX, Catalan R, Reventos J. Individual variations of serum testosterone in patients with pros- tate cancer receiving androgen deprivation therapy. BJU Int 2009;103:332–5, discussion 335.
[43]
Pickles T, Hamm J, Morris WJ, Schreiber WE, Tyldesley S. Incom- plete testosterone suppression with luteinizing hormone-releas- ing hormone agonists: does it happen and does it matter? BJU Int 2012;110:E500–7.
[44]
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566–77.
[45]
Crawford ED, Shore ND, Moul JW, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83:1122–8.
[46]
Tsushima T, Nasu Y, Saika T, et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 2001;66:135–9.[47]
Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60:64–71.[48]
Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body com- position. J Clin Oncol 2004;22:2546–53.[49]
Kunath F, Grobe HR, Rucker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hor- mone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014;6:CD009266.[50]
Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the ran- domised trials. Lancet 2000;355:1491–8.[51]
Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Data- base Syst Rev 2000:CD001526.[52]
Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term fol- low-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115:3437–45.[53]
Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a system- atic review of randomized trials. J Clin Oncol 2013;31:2029–36.[54]
Sciarra A, Salciccia S. A novel therapeutic option for castration- resistant prostate cancer: after or before chemotherapy? Eur Urol 2014;65:905–6.[55]
Botrel TE, Clark O, dos Reis RB, et al. Intermittent versus continu- ous androgen deprivation for locally advanced, recurrent or met- astatic prostate cancer: a systematic review and meta-analysis. BMC Urol 2014;14:9.[56]
Brungs D, Chen J, Masson P, Epstein RJ. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014;17:105–11.[57]
Hussain M, Tangen CM, Berry DL, et al. Intermittent versus con- tinuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314–25.[58]
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.
[59]
Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-termE U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 3 0 – 6 4 2
640